Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Novas estratégias de tratamento

Apresentamos dois estudos que comparam a eficácia de diferentes estratégias para a TARV.

   

  • *No estudo NAMSAL ANRS 12313, que comparou DTG versus EFV 400 mg, os grupos foram divididos em DTG + TDF/3TC (N=310) e EFV + TDF/3TC (N=303).

    ** No estudo NAMSAL ANRS 12313, dos 10 indivíduos qe falharam virologicamente ao regime EFV + TDF/3TC e estavam sensíveis na entrada no estudo, 9 desenvolveram algum tipo de mutação de rsistência: EFV (n=3); 3TC + EFV (n=3); EFV + TDF + 3TC (n=3).

    1.  ORKIN, C. et al. Two-drug regimen of dolutegravir plus lamivudine (DTG + 3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG + TDF/FTC) at 48 weeks in antiretroviral treatment-naïve adults with HIV-1 infection: subgroup analyses in the GEMINI studies. P021. Journal of the International AIDS Society; 21(S8):e25187, 2018.

    2. CAHN, P. et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-na€ıve adults with HIV-1 infection – 48-week results from the GEMINI studies. Abstract TUAB0106LB. In: 22nd International AIDS Conference; 2018 Jul 23-27, Amsterdam, Netherlands. Disponível em: <http://www.natap.org/2018/IAC/IAC_05.htm>. Acesso em: 05 nov. 2018.

    3. ORKIN, C. et al. Two-drug regimen of dolutegravir plus lamivudine (DTG + 3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG + TDF/FTC) at 48 weeks in antiretroviral treatment-naïve adults with HIV-1 infection: subgroup analyses in the GEMINI studies. In: HIV Drug Therapy, Glasgow 2018. Disponível em: <http://www.natap.org/2018/GLASGOW/GLASGOW_42.htm>. Acesso em: 08 nov. 2018.

    4.  COURNIL, A. et al. Dolutegravir- versus an efavirenz 400 mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial. O342. Journal of the International AIDS Society; 21(S8):e25187, 2018.

    5. COURNIL, A. et al. Dolutegravir- versus an efavirenz 400 mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial. In: HIV Drug Therapy, Glasgow 2018. Disponível em: <http://www.natap.org/2018/GLASGOW/GLASGOW_44.htm>. Acesso em: 08 nov. 2018.

    6. WORLD HEALTH ORGANIZATION (WHO). Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Disponível em: <http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18-eng.pdf?ua=1>. Acesso em: 08 nov. 2018.

    7. WORLD HEALTH ORGANIZATION (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Disponível em: <http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1>. Acesso em: 08 nov. 2018.

    8. WALMSLEY, SL. et al. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. N Engl J Med; 369:1807-18, 2013.

    9. ENCORE1 STUDY GROUP. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis; 15(7):793-802, 2015.

    10. LLIBRE, JM. et al. Genetic barrier to resistance for dolutegravir.AIDS; 17(1):56-64, 2015.